Company Overview of Argolyn Bioscience, Inc.
Argolyn Bioscience, Inc., a biotechnology company, discovers and develops peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain. Argolyn Bioscience, Inc. was incorporated in 2002 and is based in Durham, North Carolina. Argolyn Bioscience, Inc. is under liquidation.
2530 Meridian Parkway
Durham, NC 27713
Founded in 2002
Key Executives for Argolyn Bioscience, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Argolyn Bioscience, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.